Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Low adoption of pharmacogenetic testing: an exploration and explanation of the reasons in Australia|
|Citation:||Personalized Medicine, 2007; 4(2):191-199|
|David Corkindale, Helena Ward & Ross McKinnon|
|Abstract:||The research reported here sought to identify and illuminate the reasons for the low adoption of pharmacogenetic tests in Australia. The research initially established possible reasons and propositions drawn from previous studies and surveys on the problem in Europe and the literature on the adoption of innovations. A small-scale exploratory, qualitative study was undertaken in one state in Australia; clinicians and other stake-holders were interviewed about their use of or support for pharmacogenetic tests. The expected, quite extensive individual factors known to influence adoption and rejection of innovations were found to be present in the situations covered. The reasons for nonadoption that were found in previous surveys were also supported. Some other, possibly critical, reasons were also identified. The implications from this initial exploration are discussed and the prospects for the increased use of the tests proposed.|
|Keywords:||Abacovir; Adoption of innovations; Azathioprine; HER2; Perhexiline; Pharmacogenetic tests; Reasons for nonadoption; TPMT; Warfarin|
|Rights:||© 2007 Future Medicine Ltd.|
|Appears in Collections:||Medical Education Unit publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.